NCT07004582 (PR3DICT) is a clinical trial of HDR brachytherapy in Prostate Cancer, sponsored by Maastricht Radiation Oncology.

Who is sponsoring NCT07004582?

NCT07004582 is sponsored by Maastricht Radiation Oncology.

What drugs are being tested in NCT07004582?

Interventions in NCT07004582: HDR brachytherapy, Diagnostic biopsy.

What condition does NCT07004582 study?

NCT07004582 studies Prostate Cancer, Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Advanced Prostate Cancer.

Is NCT07004582 still recruiting?

NCT07004582 is currently not yet recruiting. Last updated 27 January 2026.

Last reviewed 2026-01-27 · How we verify

NCT07004582: PR3DICT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

Not yet recruiting Last updated 27 January 2026

What this trial tests

trial testing HDR brachytherapy in Prostate Cancer in 600 participants. Not yet recruiting.

Timeline

10 February 2026

Primary endpoint
30 September 2031

30 December 2031

Quick facts

Lead sponsor	Maastricht Radiation Oncology
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	600
Start date	10 February 2026
Primary completion	30 September 2031
Estimated completion	30 December 2031
Sites	3 locations across Netherlands

Drugs / interventions tested

HDR brachytherapy
Diagnostic biopsy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Prostate Cancer Metastatic Disease — all drugs for Prostate Cancer Metastatic Disease →
Prostate Cancer Recurrent — all drugs for Prostate Cancer Recurrent →
Advanced Prostate Cancer — all drugs for Advanced Prostate Cancer →

Sponsor

Maastricht Radiation Oncology — full company profile →

Who can join

18 and older, male only, with Prostate Cancer or Prostate Cancer Metastatic Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and more than a third after undergoing radiation therapy. Men with metastatic prostate cancer have particularly poor prognoses, with a five-year survival rate of only 30% to 50%. In short, it is difficult to predict which treatment, or combination of treatments, will lead to longer survival for this group of men with aggressive (metastatic) prostate cancer. In the laboratory, it is possible to grow small samples of tumors into 3D mini-tumors. These mini-tumors retain the characteristics of the patient's original tumor tissue. Various treatments can be tested on these 3D mini-tumors to determine which therapy is most effective for each individual case. There are currently two techniques available for creating these 3D mini-tumors in the lab. In this project, we aim to investigate which of these two techniques works best in order to test and personalize treatments.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recapitulating the tumour microenvironment: advancing personalised radiation therapy through organoid technology.
Lan Z, Liu J, Li L, Yang Y, et al · · 2026 · PMID 41761263 · DOI 10.1186/s13046-026-03655-0

Verify or expand the search:

Other trials of HDR brachytherapy

Trials testing the same drug.

NCT03424850 — Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy · Phase 1, PHASE2 · recruiting
NCT00911079 — Pilot Study of a Catheter-based Ultrasound Hyperthermia System · NA · terminated

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Maastricht Radiation Oncology trials

Trials by the same sponsor.

NCT07501845 — Registry Maastro Applicator · recruiting
NCT06024941 — Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer · Phase 2 · withdrawn
NCT05182437 — Precision Radiation Treatment for Epilepsy (PRECISION) · NA · active not recruiting
NCT02432417 — The Addition of Chloroquine to Chemoradiation for Glioblastoma, · Phase 2 · withdrawn
NCT05287971 — Standard of Care Lifestyle Support for Stage III NSCLC Patients · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07004582 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maastricht Radiation Oncology
Last refreshed: 27 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07004582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing